1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Chronic Disease Market Trends
  5. > Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Global Clinical Trials Review, H2, 2015

Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Global Clinical Trials Review, H2, 2015

Summary

GlobalData's clinical trial report, “Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Global Clinical Trials Review, H2, 2015" provides an overview of Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) clinical trials scenario. This report provides top line data relating to the clinical trials on Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table Of Contents

Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Global Clinical Trials Review, H2, 2015
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Report Guidance 5
Clinical Trials by Region 6
Clinical Trials and Average Enrollment by Country 7
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) to Cardiovascular Clinical Trials 15
Clinical Trials by Phase in G7 Countries 17
Clinical Trials in G7 Countries by Trial Status 18
Clinical Trials by E7 Countries: Proportion of Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) to Cardiovascular Clinical Trials 20
Clinical Trials by Phase in E7 Countries 22
Clinical Trials in E7 Countries by Trial Status 23
Clinical Trials by Phase 24
In Progress Trials by Phase 25
Clinical Trials by Trial Status 26
Clinical Trials by End Point Status 28
Subjects Recruited Over a Period of Time 29
Clinical Trials by Sponsor Type 30
Prominent Sponsors 31
Top Companies Participating in Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics Clinical Trials 33
Prominent Drugs 35
Latest Clinical Trials News on Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) 36
Nov 08, 2015: Isis Pharmaceuticals Reports Positive Clinical Data From Lp(a) Lowering Drug 36
Clinical Trial Profile Snapshots 37
Appendix 95
Abbreviations 95
Definitions 95
Research Methodology 96
Secondary Research 96
About GlobalData 97
Contact Us 97
Disclaimer 97
Source 98

List of Tables
Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics, Global, Clinical Trials by Region, 2015* 6
Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015* 8
Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015* 9
Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2015* 10
Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics Clinical Trials, Europe, Top Five Countries, 2015* 11
Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics Clinical Trials, North America, Top Countries, 2015* 12
Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2015* 13
Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics Clinical Trials, Central and South America, Top Countries, 2015* 14
Proportion of Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) to Cardiovascular Clinical Trials, G7 Countries (%), 2015* 16
Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics, G7 Countries, Clinical Trials by Phase, 2015* 17
Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015* 19
Proportion of Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) to Cardiovascular Clinical Trials, E7 Countries (%), 2015* 21
Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics, E7 Countries, Clinical Trials by Phase, 2015* 22
Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2015* 23
Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics, Global, Clinical Trials by Phase, 2015* 24
Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics, Global, Clinical Trials In Progress by Phase 2015* 25
Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics, Global, Clinical Trials by Trial Status, 2015* 27
Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics Clinical Trials, Global, by End Point Status, 2015* 28
Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2010-2014 29
Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2015* 30
Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics Clinical Trials, Global, Key Sponsors, 2015* 32
Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015* 34
Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015* 35

List of Figures
Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics, Global, Clinical Trials by Region (%), 2015* 6
Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015* 7
Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015* 9
Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2015* 10
Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2015* 11
Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics Clinical Trials, North America, Top Countries (%), 2015* 12
Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2015* 13
Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2015* 14
Proportion of Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) to Cardiovascular Clinical Trials, G7 Countries (%), 2015* 15
Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics, G7 Countries, Clinical Trials by Phase, 2015* 17
Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015* 18
Proportion of Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) to Cardiovascular Clinical Trials, E7 Countries (%), 2015* 20
Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics, E7 Countries, Clinical Trials by Phase, 2015* 22
Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2015* 23
Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics, Global, Clinical Trials by Phase (%), 2015* 24
Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics, Global, Clinical Trials In Progress by Phase, 2015* 25
Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics, Global, Clinical Trials by Trial Status, 2015* 26
Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics Clinical Trials, Global, by End Point Status, 2015* 28
Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2010-2014 29
Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2015* 30
Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics Clinical Trials, Global, Key Sponsors, 2015* 31
Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015* 33
Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015* 35
GlobalData Methodology 96

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Global Cardiovascular Disease Market to 2022 - Sanofi and Novartis to Become Market Leaders as Praluent and Entresto Drive Revenue Growth

Global Cardiovascular Disease Market to 2022 - Sanofi and Novartis to Become Market Leaders as Praluent and Entresto Drive Revenue Growth

  • $ 4995
  • Industry report
  • October 2016
  • by GBI Research

Global Cardiovascular Disease Market to 2022 - Sanofi and Novartis to Become Market Leaders as Praluent and Entresto Drive Revenue Growth Summary Cardiovascular disease (CVD) covers a range of difference ...

Chronic Heart Failure - Market Insights, Epidemiology and Market Forecast-2023

Chronic Heart Failure - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Chronic Heart Failure - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and ...

Peripheral Arterial Disease - Market Insights, Epidemiology and Market Forecast-2023

Peripheral Arterial Disease - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

DelveInsight’s Peripheral Arterial Disease - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global market trends of the Peripheral Arterial ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.